|
Session 105
Poster Abstracts
Interplay among HIV Resistance, Fitness and Outcome
Wednesday, 1:30 - 3:30 pm
Poster Hall |
623
 |
Modeling and Estimation of Replication Fitness of HIV-1 in vitro Experiments Using a Growth Competition Assay
Hulin Wu*1, Y Huang2, C Dykes1, D Liu1, J Ma1, A Perelson3, and L Demeter1
1Univ of Rochester, NY, US; 2Univ of South Florida, Tampa, US; and 3Los Alamos Natl Labs, NM, US |
| 624 |
Replicative Capacity Effect of Mutations that Are Associated with Efavirenz Hypersusceptibility
Nancy Shulman*1, J Mellors2, S Clark2, R Bosch3, and N Parkin4
1Stanford Univ Sch of Med, Palo Alto, CA, US; 2Univ of Pittsburgh Sch of Med, PA, US; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; and 4Monogram Biosci, South San Francisco, CA, US |
| 625 |
Replication Characteristics of Transmitted Multi-drug-resistant HIV-1 Isolates from Recently Infected, ART-naive Patients
Hiroshi Mohri*, P Jean-Pierre, L Berry, A Kim, C Chung, V Manuelli, D Boden, S Mehandru, A Shet, and M Markowitz
Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY, US |
| 626 |
Decreased Viral Fitness in Resistance-associated Mutations in vivo
C Kitchen, P Krogstad, and Scott Kitchen*
David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US |
| 627 |
Mutation Interactions Modulate the Fitness Cost of Drug Resistance Mutations in Transmitted Isolates: Implications for Persistence of Transmitted Resistance
M E j, D Bennett, W Heneine, and J Gerardo Garcia-Lerma*
CDC, Atlanta, GA, US |
628
|
Prolonged Persistence of M184V Mutation and Phenotypic Resistance to Lamivudine in Adults with Multi-drug-resistant HIV-1 Infection Interrupting Treatment with Reverse Transcriptase Inhibitors
Roger Paredes*1,2, V Marconi1, R Hoh3, J Martin3, C Petropoulos4, S Deeks3, and D Kuritzkes1
1Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US; 2Fndn irsiCaixa, Badalona, Spain; 3Univ of California, San Francisco and San Francisco Gen Hosp, US; and 4Monogram Biosci, South San Francisco, CA, US |
629
|
in vivo Fitness of Enfuvirtide-resistant HIV-1 Estimated by Allele-specific PCR during Partial Treatment Interruption and Pulse Intensification
Vincent Marconi*1,2, S Bonhoeffer3, R Paredes1, J Lu1, R Hoh4, J Martin4, S Deeks4, and D Kuritzkes1
1Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US; 2Wilford Hall US Air Force Med Ctr, San Antonio, TX, US; 3ETH Zurich, Switzerland; and 4Univ of California, San Francisco, US |
| 630 |
Transmission of HIV-1 with Drug-resistance Mutations that Evolve in the Absence of ART Results in a Mild Initial Decline of CD4 Cell Counts
D Bezemer1, A de Ronde2, M Prins1, K Porter3, Deenan Pillay*4, B Masquelier5, F Dabis6, N Back2, S Jurriaans2, L van der Hoek2, and CASCADE Collaboration
1Municipal Hlth Svc, Amsterdam, The Netherlands; 2Academic Med Ctr, Amsterdam, The Netherlands; 3Med Res Council Clin Trials Unit, London, UK; 4Univ Coll London, UK; 5Ctr Hosp Univ, Bordeaux, France; and 6Bordeaux Univ Hosp, INSERM U593, France |
| 631 |
Viral Replication Capacity under Varying Adherence-adjusted Cmin Drug Levels Explains Differing NNRTI and PI Adherence/Resistance Relationships
David Bangsberg*1, E Acosta2, R Gupta3, D Guzman1, E Riley1, R Harrigan4, N Parkin5, and S Deeks6
1San Francisco Gen Hosp, Univ of California, US; 2Univ of Alabama at Birmingham, US; 3Harvard Med Sch, Boston , MA, USA; 4BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; 5Monogram Biosci, South San Francisco, CA, US; and 6San Francisco Gen Hosp, CA, US |
|
